Today's life science industry is changing rapidly. Overcoming endless evolving challenges is crucial to success for all businesses large and small. Small and medium-sized biotech companies are creative, efficient, energetic, and flexible. However, they are often challenged by limited resources. These can become barriers, impeding continuous growth and greater success. Large corporations need to find new growth opportunities to foster innovation and increase efficiency. Life Science Quest, with our experience and resources across a broad spectrum of fields in health care and life sciences, provides high quality, results-oriented services to help businesses overcome barriers and maximize their potential.
By engaging our high quality services, Life Science Quest helps businesses to promote innovative technology, unlock global market potential, and empowers their overall growth.
Life Science Quest co-founder Ruobing Xia oversees global strategy, business development, and commercial operations. An accomplished marketer, business development professional, and entrepreneur with extensive global experience, Ruobing co-founded several startups where she is responsible for global strategy, business development, and commercial operations. Previously, she had a progressive career with Eli Lilly and Boehringer Ingelheim where she managed hundred million dollar product launches and promotional budgets, developed sales and marketing strategies, and generated licensing deals. This was supported by her earlier career in foreign trade, international banking, finance, and venture development. Ruobing holds Masters degrees in International Affairs (finance) from Columbia University in New York City and Business Administration (MBA) from IMD in Lausanne, Switzerland.
Life Science Quest co-founder Yongmei Li oversees all of our research and scientific endeavors. Yongmei has more than ten years of experience working in Boehringer Ingelheim Pharmaceuticals, Inc. As Senior Principal Scientist, she led a group of scientists in drug metabolism and pharmacokinetics in support of new drug development. She had successfully led the research on drug metabolism and drug-drug interactions for a second-generation anti-HCV drug, and relevant regulatory submissions in US, Europe, and Japan. Yongmei currently serves as Vice President of Sino-American Pharmaceutical Professionals Association - Connecticut chapter (SAPA-CT). She holds a Ph.D. in Pharmacognosy (Natural Product Chemistry) from the College of Pharmacy, University ofIllinois, and a MS in Pharmacognosy and a BS degree in Pharmacy from the West China University of Medical Sciences.
Dr. Wolfgang Renz has been a leader for startups and corporations over the last two decades, delivering significant commercial successes by identifying and exploiting new business opportunities across the health care industry. Dr. Renz is former Corporate Vice President at Boehringer Ingelheim GMBH, where he had global responsibility for new business models and healthcare innovation. His unique combination of medical expertise -- he is Adjunct Professor of Experimental Surgery on McGill University’s Faculty of Medicine -- with global business acumen enable Dr. Renz to be effective in leadingM&A opportunities in pharmaceutical industry, and in driving the growth of new health care businesses.
Toni Rinow is a catalyst for growth and expansion and is well known for accelerating revenue streams through acquisitions, corporate development, sales and marketing, and financing. With a proven track record of success in international corporate development and the sales and financing of companies in the healthcare market, Toni is quickly becoming a recognized thought leader in healthcare innovation, convergence, and health/IT investments. Focusing on strategic growth, Toni is that rare C-level executive with blended business expertise and science and engineering brainpower. In addition to her MBA from McGill University, she holds a doctorate in physical chemistry from the Université de Montréal (Ph.D), and a chemical engineering degree from the European Higher Institute of Chemistry in Strasbourg, France. Her professional career has included leadership roles in both public and private pharmaceutical and healthcare organizations, where she spearheaded acquisitions across Canada, Latin America, and India, and supported the transition of two biotechnology companies to an initial public offering at the Toronto Stock Exchange.
Joy Gupta is a consultant and subject matter expert in Market Research and Competitive Intelligence. With over 30 years global experience in Life Sciences and Consumer Packaged Goods, Joy has covered the gamut of commercial analytics supporting new drug launches, pipeline evaluations, branding, communications, and business planning. From 1982 until 2002 he held progressively important leadership positions with Procter & Gamble and other global Fortune 500 companies. In 2002, he founded his own consulting practice and worked with reputed firms including Boehringer-Ingelheim and Fresenius-Kabi. More recently, he has been involved with several startups. Joy typically engages in hands-on work with cross-functional teams and senior management. He provides analytic leadership culled from experience working with multiple healthcare stakeholders across office- and hospital-based care settings. Joy has also directed industry studies on important contemporary topics such as orphan drugs and managing big data, and frequently brings this knowledge into his assignments. Joy has presented papers at several conferences. He holds an MBA from India. He lives in New York City.
Dr. Pion is a pioneer in telemedicine and tele-health. He is a physician, visionary, and business leader that combines a practitioner's perspective with healthcare industry expertise and corporate experience to provide assistance and wisdom to innovative companies. He draws upon significant experience in leadership roles in both public and private healthcare companies. He has a notable record of developing companies and defining business strategies that break down barriers and provide quality patient services. Dr. Pion began his career in academics, serving on the faculty of the University of Washington and the University of Hawaii. Having recognized at an early stage the benefits technology and new media bring to the practice of medicine, he became a pioneer in the area of medical telecommunications and has worked in that area for more than 30 years. He served as a full-time medical correspondent for KNBC television in Los Angeles prior to founding the Hospital Satellite Network, the nation's first daily satellite-delivered television service providing programming for hospital-based health professionals and patients. He is a Clinical Professor at the UCLA School of Medicine and a Fellow of the American College of Obstetricians and Gynecologists. Dr. Pion graduated from New York University (B.A., Phi Beta Kappa) and New York Medical College (M.D., Alpha Omega Alpha).
A veteran of over 20 years in the pharmaceutical industry in both the US and China, Gan has accumulated experiences in a broad spectrum of commercialization areas, including sales and marketing management, new product launch and portfolio strategies, and branding and lifecycle management. As a returnee, Gan has spent the past eight years working at major MNCs such as GSK and Cardinal Health, as well as in a digital healthcare start-up. In October 2015 he formed his own consulting firm, HG-Healthcare Consulting in Shanghai, helping MNCs and local healthcare clients in a variety of areas including portfolio strategy, market entry, new product pre-launch strategy, and overseas M&A and strategic partnerships. Gan obtained his B.S from Peking University, an MS from Rutgers, and his MBA from NYU’s Stern School of Business.